Department of Veterans Affairs Rejects Biogen’s Aduhelm, PBM Criticizes Controversial Drug

August 12, 2021

The Department of Veterans Affairs (VA) has rejected Biogen’s expensive Aduhelm for use in Alzheimer’s disease. The VA is the latest agency to refuse the drug; its approval by the Food and Drug Administration’s is facing scrutiny. However, despite not being added to the VA’s formulary, the drug will still be accessible in certain instances where other therapies were not effective.

A VA spokesperson remarked, “It is not being added to the VA National Formulary due to the risk of significant adverse drug events and to the lack of evidence of a positive impact on cognition.” Read more here.

(Source: Zachary Brennan, Endpoints News, 8/11/21)

Share This Story!